Report Highlights

Varicocele Treatment in the U.S.: Market Overview

The U.S. varicocele treatment market, valued at USD 412 million in 2024, sits within the broader urology and interventional radiology device sector. Its structure reflects a regulatory split: embolization and microsurgical repair are reimbursed under Medicare Physician Fee Schedule codes administered by the Centers for Medicare and Medicaid Services, while devices are cleared by the Food and Drug Administration. Government has set reimbursement and device approval rules, while private providers and device makers decide adoption.

Private sector has led clinical adoption. Interventional radiologists and urologists at hospital networks and ambulatory surgery centers have shifted toward percutaneous embolization since the 2010s, with Cook Medical and Boston Scientific supplying coil and sclerosant kits. Microsurgical subinguinal varicocelectomy remains the dominant urological pathway, supported by Carl Zeiss Meditec operating microscopes. Hospital outpatient payment classifications under the Outpatient Prospective Payment System have steered procedures toward ambulatory settings, shaping which providers invest in the equipment.

Policy-Driven Growth in Varicocele Treatment in the U.S.

The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) established the Quality Payment Program, under which urologists reporting through the Merit-based Incentive Payment System (MIPS) earn payment adjustments tied to measured performance. Varicocele repair is billed under CPT 55530 for open varicocelectomy and CPT 37241 for venous embolization, and both codes are valued annually in the CMS Medicare Physician Fee Schedule. MIPS reporting favors standardized, documented procedures, which steers practices toward validated microsurgical and embolization protocols and the equipment those protocols require.

The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), published January 2024, requires Medicare Advantage organizations and Medicaid and CHIP managed care plans to issue prior authorization decisions within 72 hours for expedited requests and seven calendar days for standard requests, starting January 1, 2026. Faster authorization compresses the interval between urology consultation and treatment, increasing throughput for covered embolization in Medicare Advantage panels. Practices with pre-authorized device inventories gain volume, since coil and sclerosant kits are consumed per case and must be stocked in advance.

Regulatory Barriers and Compliance Costs for Varicocele Treatment

Embolization coils and sclerosants are Class II devices requiring 510(k) premarket notification under the Federal Food, Drug, and Cosmetic Act, administered by the FDA Center for Devices and Radiological Health. Clearance targets a 90-FDA-day review under MDUFA V performance goals, excluding the time manufacturers take to respond to information requests. Manufacturers must also comply with the Quality Management System Regulation at 21 CFR Part 820, aligned with ISO 13485 and effective February 2, 2026, which adds certification costs for smaller suppliers.

State certificate-of-need programs administered by state health departments create a second barrier. New York’s program under Public Health Law Article 28 and North Carolina’s certificate-of-need review require approval before new ambulatory surgical capacity or fixed angiography equipment is installed. Applications typically take several months and carry filing and legal costs that delay independent clinics from adding embolization suites.

Policy-Created Opportunities in U.S. Varicocele Care

Medicare Advantage plans must meet the 72-hour expedited and seven-day standard prior authorization timelines under CMS-0057-F from January 1, 2026, creating demand for electronic prior authorization platforms integrated with urology electronic health records. The same rule requires Prior Authorization application programming interfaces based on HL7 FHIR, which gives software vendors a defined technical specification to build against. Vendors supplying compliant platforms can serve hospital urology groups that lack in-house integration capacity.

Outpatient migration under the Outpatient Prospective Payment System and the ASC Covered Procedures List creates a second opportunity. Independent ambulatory surgery centers equipped with angiography suites and surgical microscopes can perform both embolization and microsurgical repair without hospital overhead. Operators that secure certificate-of-need approval in states regulating ambulatory surgical capacity gain first-mover access to these procedure volumes.

Market at a Glance

Leading Market Participants

• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• Terumo Corporation
• Merit Medical Systems
• Teleflex Incorporated
• Carl Zeiss Meditec AG
• Stryker Corporation
• Cardinal Health
• Johnson & Johnson MedTech

Regulatory and Policy Environment for Varicocele Treatment in the U.S.

The primary legislation is the Federal Food, Drug, and Cosmetic Act, which the FDA enforces for device clearance under 21 U.S.C. 360(k) and for quality systems under 21 CFR Part 820. Payment and fraud controls sit under Title XVIII of the Social Security Act, enforced by CMS and the HHS Office of Inspector General, including the Anti-Kickback Statute at 42 U.S.C. 1320a-7b(b). Manufacturers must also report payments to physicians under the Open Payments program, codified at 42 U.S.C. 1320a-7h, and prior authorization compliance under CMS-0057-F begins January 1, 2026.

Upcoming changes include the full QMSR enforcement from February 2, 2026 and the negotiation of MDUFA VI ahead of the MDUFA V expiration on September 30, 2027. Compared with regional peers, the U.S. 510(k) pathway is faster than the EU Medical Device Regulation (EU) 2017/745, which requires notified body certification and extended transition timelines. Health Canada licensing under the Medical Devices Regulations (SOR/98-282) is closer to the U.S. model, but it offers fewer routes for rapid device clearance.

Long-Term Policy Outlook for Varicocele Treatment in the U.S.

MDUFA VI reauthorization will reset FDA review goals for embolization devices before 2028, shaping how quickly new coil and sclerosant products reach U.S. urology suites. Annual CMS Physician Fee Schedule and Outpatient Prospective Payment System rules through 2032 will continue to rebalance payment between hospital outpatient departments and ambulatory surgery centers. These updates will determine the pace at which procedure volume shifts toward outpatient settings.

By 2032, prior authorization interoperability under CMS-0057-F will be fully embedded in Medicare Advantage workflows, reducing treatment delays for covered embolization. Full QMSR enforcement will consolidate the supplier base, favoring established manufacturers with validated quality systems. The combined effect will sustain growth at a 5.4% CAGR, with policy rather than clinical demand setting the pace of market expansion.